Cancer research at BESSY II: Binding Mechanisms of Therapeutic Substances Deciphered
The study is displayed on the cover of the journal Chemmedchem. © Chemmedchem/VCH Wiley
In tumor cells, the DNA is altered in comparison to normal body cells. How such changes can be prevented or inhibited is an exciting field of research with great relevance for the development of cancer treatments. An interdisciplinary team has now analysed the possible binding mechanisms in certain therapeutic substances from the tetrazole hydrazide group using protein crystallography at BESSY II.
Certain proteins such as human histone demethylases, including the KDM4 protein, play a role in the development of tumour cells. They bind to the DNA and modify it so that the cell can become cancerous. Therapeutic substances that are able to inhibit or even reverse such changes are of particular interest.
Biochemist Prof. Dr. Udo Heinemann from the Max Delbrück Centre in Berlin-Buch is investigating such processes. In cooperation with chemists led by Prof. Dr. Andreas Link from the University of Greifswald and the team led by Dr. Manfred Weiss at the HZB, he has now investigated how and where certain therapeutic substances from the tetrazole hydrazide group dock to these protein molecules and thus inhibit their harmful effect.
KDM4 protein crystals analysed
Link initially produced variations of tetrazole hydrazide substances. For structural analysis, crystals had to be grown from KDM4 proteins - a difficult task that Dr. Piotr Malecki and Manfred Weiss had taken on at the HZB. The KDM4 protein crystals were then soaked in a specific substance before being analyzed with strong X-rays on the MX beamlines of BESSY II. A refined analysis showed not only the three-dimensional architecture of the KDM4 protein, but also exactly where the active substances had docked to the KDM4 molecule.
"This class of substances has not yet been structurally investigated," explains Manfred Weiss. And Udo Heinemann from the MDC explains: "We will now evaluate where there are opportunities to dock even stronger within the 3D structure of the KDM4. Then we might also be able to develop drugs that inhibit the KDM4 even more and thus have the potential to become a therapeutic."
- What vibrating molecules might reveal about cell biologyInfrared vibrational spectroscopy at BESSY II can be used to create high-resolution maps of molecules inside live cells and cell organelles in native aqueous environment, according to a new study by a team from HZB and Humboldt University in Berlin. Nano-IR spectroscopy with s-SNOM at the IRIS beamline is now suitable for examining tiny biological samples in liquid medium in the nanometre range and generating infrared images of molecular vibrations with nanometre resolution. It is even possible to obtain 3D information. To test the method, the team grew fibroblasts on a highly transparent SiC membrane and examined them in vivo. This method will provide new insights into cell biology.
- Sasol and HZB deepen collaboration with strategic focus on digitalisationSasol Research & Technology and Helmholtz Zentrum Berlin (HZB) are expanding their partnership into the realm of digitalisation, building on their joint efforts in the CARE-O-SENE project and an Industrial Fellowship launched earlier this year. This new initiative marks a significant step forward in leveraging digital technologies to accelerate catalyst innovation and deepen scientific collaboration.
- Technology Transfer Prize Ceremony 2025This year’s Technology Transfer Prize Ceremony will take place on October 13 at 2 pm in the Lecture Hall, BESSY II Building, Adlershof.